BMI's Executive Summary

[TOP]

Switzerland has an advanced pharmaceutical market and per-capita expenditure is among the highest in the world at an estimated US$743.4 in 2006. Consumption centres around patented pharmaceuticals, with Switzerland providing a ready market for cutting-edge therapies. Meanwhile, high-levels of out-of-pocket expenditure have resulted in the development of a mature and competitive consumer health sector. Overall market growth should expand at a CAGR of 5.73% over the forecast period to reach a value of US$7.69bn.

In the latest quarter, most market activity has been centred around the major domestic players, with Novartis having an especially busy few months. The multinational has recently announced restructuring plans involving shedding 2,500 jobs, or 2.5% of its workforce, as it hopes to achieve savings of US$1.6bn a year until 2010. Meanwhile, Sandoz, Novartis' generics arm has announced that it is to launch a generic version of biotech anaemia treatment epoetin alfa (EPO), the primary ingredient in US-based Amgen's blockbuster Epogen. BMI's views the launch as a major step forward for the rapidly growing biosimilars industry.

In terms of M&A activity, the major deal saw Swiss pharmaceutical producer and wholesaler Galenica acquire Canadian biotech Aspreva in a deal worth US$900mn. The purchase is one of the largest ever in the Canadian pharmaceutical sector and has provided a ringing endorsement for Canada's biotech industry, often criticised as a difficult environment to work in, while also highlighting the continual interest of the major Swiss players in snapping up biotech assets.

Meanwhile, Switzerland takes first place in BMI's revised Business Environment Rankings for the Western European region. We have completely overhauled the methodology giving greater weight to regulatory factors affecting the drug market, while utilising a more nuanced analysis of country-specific economic and political factors. Switzerland's position derives mainly from its excellent regulatory system and high per-capita expenditure.

Contents

[TOP]

Chapter 1 - Executive Summary

Switzerland Pharmaceuticals & Healthcare Industry SWOT

Political SWOT

Economic SWOT

Chapter 2 - Business Environment Rankings

Chapter 3 - Western Europe

Table: Western Europe Business Environment Rankings

Business Environment Ranking

Economics - Long-Term Risk

Politics - Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 4 - Switzerland: Market Summary

Chapter 5 - Regulatory Regime

Chapter 6 - Intellectual Property Developments

Chapter 7 - Pricing & Reimbursement Issues

Table: A Comparison Of Medicine Prices In Western Europe

Chapter 8 - Industry Developments

Chapter 9 - Healthcare Sector

Pharmaceuticals Sector

Table - Domestic Pharmaceutical Companies In Switzerland

Chapter 10 - Domestic Industry

Multinational Sector

R&D Sector

Hospital Sector

Pharmacy Sector

Biotech Sector

Chapter 11 - Industry Forecast Scenario

Chapter 12 - Overall Market Forecast

Table: Health Expenditure Indicators

Key Growth Factors - Industry

Table: Health Expenditure Indicators

Key Growth Factors - Macroeconomic

Table: Switzerland - Macroeconomic Forecasts

Prescription Market Forecast

Table: Switzerland Prescription Drugs Market Forecast Indicators

OTC Market Forecast

Table: Switzerland OTC Market Forecast Indicators

Generics And Branded Market Forecasts

Table: Switzerland Generics & Branded Market Forecast Indicators

Export/Import Forecasts

Table: Switzerland Pharmaceuticals Exports & Imports Forecast Indicators

Key Risks To BMI's Forecast Scenario

Chapter 13 - Competitive Landscape

Chapter 14 - Company Profiles

Leading Multinational Manufacturers

GSK

Pfizer

Sanofi-Aventis

Merck & Co

Indigenous Manufacturer Profiles

Novartis

Roche

Serono

Chapter 15 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 16 - Appendix: Switzerland Demographic Data

Section 1: Population

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption And Stratification

Table: Wages Per Year

Competitive Landscape for Europe Pharmaceuticals and Healthcare: Sample of Companies Ranked

[TOP]

Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.

Network of European Pharmaceutical & Healthcare Sources

[TOP]

BMI's Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include: